External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ESMO Asia 2023
Roche at

ESMO Asia 2023

December 01 - December 03
Singapore, Republic of Singapore / Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:00 AM
Duration 60mins Singapore, Republic of Singapore
HCC illuminated: Exploring future frontiers with systemic immunotherapies
Han Chong Toh, Ann Lii-Cheng, Hui-Chuan Sun, Pierce Chow
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:00 AM
Duration 75mins Singapore, Republic of Singapore
Integrated Analysis of Randomized Controlled Trials IMpower130 and IMpower132 for Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Makoto Nishio1, Satoshi Watanabe2, Hibiki Udagawa3, Naoko Aragane4, Yuki Nakagawa5, Yuki Kobayashi5, Haruhiro Saito6
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 75mins Singapore, Republic of Singapore
IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Masatoshi Kudo1, Tatsuya Yamashita2, Richard S. Finn3, Peter R. Galle4, Michel Ducreux5, Ann-Lii Cheng6, Kaoru Tsuchiya7, Naoya Sakamoto8, Shuhei Hige9, Ryosuke Take10, Kyoko Yamada10, Takashi Asakawa10, Yuki Nakagawa10, Masafumi Ikeda11
Oncology | Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:15 AM
Duration 5mins Singapore, Republic of Singapore
Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy in patients from Asia with resected, early-stage ALK+ NSCLC: a subanalysis of ALINA
Jin Seok Ahn, Yi-Long Wu, Rafal Dziadziuszko, Fabrice Barlesi, Makoto Nishio, Dae Ho Lee, Jong-Seok Lee, Wenzhao Zhong, Hidehito Horinouchi, Weimin Mao, Shun Lu, Qun Wang, Cheng-Ta Yang, Krittiya Korphaisarn, Tingting Xu, Lilian Bu, Astrid Scalori, Patricia Petric, Karl Redhead, Benjamin J. Solomon
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.